33 results
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
demand for Apexigen’s products, injury to Apexigen’s reputation, costs to defend the related litigation, a diversion of management’s time … or eventual outcome, product liability claims may result in impairment of Apexigen’s business reputation, withdrawal of clinical trial participants, costs
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:03pm
to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources, and substantial monetary awards … claims. Regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:02pm
, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion … result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management’s
POS AM
iyzh2gbl9
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
updx8wwvrvly9rzz
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
frjejbxqp fpx
9 Sep 22
Prospectus supplement
4:40pm
424B3
xwlnipxtuqf2mi7j926
9 Sep 22
Prospectus supplement
4:38pm
424B3
vwkhd
6 Jul 22
Prospectus supplement
4:18pm
425
a1slw 42s4t82wjp
14 Jun 22
Business combination disclosure
6:25pm
S-4/A
pibbncdx28r dndfh7p
23 May 22
Registration of securities issued in business combination transactions (amended)
8:00pm